Changes in main clinical, lab and therapeutic features after the first 12 weeks of dapagliflozin in the efficacy cohort (n = 83).
| . | Baseline . | 12 weeks . | P . |
|---|---|---|---|
| Body weight (kg) | 82.8 ± 17.3 | 80.6 ± 16.9 | <.001 |
| BMI (kg/m2) | 28.1 (25.2–31.7) | 27.4 (24.6–31.0) | <.001 |
| eGFR (mL/min/1.73 m2) | 49.1 ± 16.5 | 50.1 ± 19.6 | .297 |
| Albuminuria (mg/day) | 180 (100–380) | 120 (50–310) | <.001 |
| Potassium (mmol/L) | 4.6 ± 0.5 | 4.5 ± 0.5 | .585 |
| Total cholesterol (mg/dL) | 142 (119–173) | 141 (116–160) | .168 |
| LDL cholesterol (mg/dL) | 72 (53–97) | 74 (52–93) | .708 |
| Triglycerides (mg/dL) | 127 (85–170) | 107 (90–153) | .283 |
| Hemoglobin (g/dL) | 13.1 ± 1.8 | 13.9 ± 1.7 | <.001 |
| Albumin (g/dL) | 4.2 ± 0.4 | 4.2 ± 0.4 | .967 |
| Urinary sodium excretion (mmol/day) | 125 (77–128) | 113(77–168) | .512 |
| . | Baseline . | 12 weeks . | P . |
|---|---|---|---|
| Body weight (kg) | 82.8 ± 17.3 | 80.6 ± 16.9 | <.001 |
| BMI (kg/m2) | 28.1 (25.2–31.7) | 27.4 (24.6–31.0) | <.001 |
| eGFR (mL/min/1.73 m2) | 49.1 ± 16.5 | 50.1 ± 19.6 | .297 |
| Albuminuria (mg/day) | 180 (100–380) | 120 (50–310) | <.001 |
| Potassium (mmol/L) | 4.6 ± 0.5 | 4.5 ± 0.5 | .585 |
| Total cholesterol (mg/dL) | 142 (119–173) | 141 (116–160) | .168 |
| LDL cholesterol (mg/dL) | 72 (53–97) | 74 (52–93) | .708 |
| Triglycerides (mg/dL) | 127 (85–170) | 107 (90–153) | .283 |
| Hemoglobin (g/dL) | 13.1 ± 1.8 | 13.9 ± 1.7 | <.001 |
| Albumin (g/dL) | 4.2 ± 0.4 | 4.2 ± 0.4 | .967 |
| Urinary sodium excretion (mmol/day) | 125 (77–128) | 113(77–168) | .512 |
Data are mean ± standard deviation or median (IQR).
Changes in main clinical, lab and therapeutic features after the first 12 weeks of dapagliflozin in the efficacy cohort (n = 83).
| . | Baseline . | 12 weeks . | P . |
|---|---|---|---|
| Body weight (kg) | 82.8 ± 17.3 | 80.6 ± 16.9 | <.001 |
| BMI (kg/m2) | 28.1 (25.2–31.7) | 27.4 (24.6–31.0) | <.001 |
| eGFR (mL/min/1.73 m2) | 49.1 ± 16.5 | 50.1 ± 19.6 | .297 |
| Albuminuria (mg/day) | 180 (100–380) | 120 (50–310) | <.001 |
| Potassium (mmol/L) | 4.6 ± 0.5 | 4.5 ± 0.5 | .585 |
| Total cholesterol (mg/dL) | 142 (119–173) | 141 (116–160) | .168 |
| LDL cholesterol (mg/dL) | 72 (53–97) | 74 (52–93) | .708 |
| Triglycerides (mg/dL) | 127 (85–170) | 107 (90–153) | .283 |
| Hemoglobin (g/dL) | 13.1 ± 1.8 | 13.9 ± 1.7 | <.001 |
| Albumin (g/dL) | 4.2 ± 0.4 | 4.2 ± 0.4 | .967 |
| Urinary sodium excretion (mmol/day) | 125 (77–128) | 113(77–168) | .512 |
| . | Baseline . | 12 weeks . | P . |
|---|---|---|---|
| Body weight (kg) | 82.8 ± 17.3 | 80.6 ± 16.9 | <.001 |
| BMI (kg/m2) | 28.1 (25.2–31.7) | 27.4 (24.6–31.0) | <.001 |
| eGFR (mL/min/1.73 m2) | 49.1 ± 16.5 | 50.1 ± 19.6 | .297 |
| Albuminuria (mg/day) | 180 (100–380) | 120 (50–310) | <.001 |
| Potassium (mmol/L) | 4.6 ± 0.5 | 4.5 ± 0.5 | .585 |
| Total cholesterol (mg/dL) | 142 (119–173) | 141 (116–160) | .168 |
| LDL cholesterol (mg/dL) | 72 (53–97) | 74 (52–93) | .708 |
| Triglycerides (mg/dL) | 127 (85–170) | 107 (90–153) | .283 |
| Hemoglobin (g/dL) | 13.1 ± 1.8 | 13.9 ± 1.7 | <.001 |
| Albumin (g/dL) | 4.2 ± 0.4 | 4.2 ± 0.4 | .967 |
| Urinary sodium excretion (mmol/day) | 125 (77–128) | 113(77–168) | .512 |
Data are mean ± standard deviation or median (IQR).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
